Elinzanetant: Relief for Breast Cancer & Menopause Symptoms
- Elinzanetant, a novel neurokinin-targeted therapy, offers relief for women experiencing moderate-to-severe vasomotor symptoms, such as hot flashes and night sweats, linked to endocrine therapy for hormone receptor (HR)-positive...
- Fatima Cardoso from the Champalimaud Foundation, involved women aged 18 to 70 undergoing endocrine therapy for HR-positive breast cancer or its prevention.
- The results showed a significant reduction in the frequency of moderate-to-severe vasomotor symptoms among those receiving elinzanetant.
Elinzanetant emerges as a promising solution for women battling hormone receptor (HR)-positive breast cancer, significantly reducing debilitating vasomotor symptoms like hot flashes and night sweats. Groundbreaking findings from a phase 3 trial presented at ASCO 2025 reveal that elinzanetant, a novel neurokinin-targeted therapy, provides substantial relief compared to a placebo. The study, featured in the New England Journal of medicine, highlights a considerable decrease in the frequency of moderate-to-severe vasomotor episodes.While adverse events were noted, they were largely manageable. Find thorough insights, all curated by News Directory 3. Learn about the drug’s journey, and anticipate its future impact on symptom management.Discover what’s next …
Elinzanetant reduces Vasomotor Symptoms in Breast Cancer Patients
Elinzanetant, a novel neurokinin-targeted therapy, offers relief for women experiencing moderate-to-severe vasomotor symptoms, such as hot flashes and night sweats, linked to endocrine therapy for hormone receptor (HR)-positive breast cancer. Findings from a phase 3 trial were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and concurrently published in the New England Journal of Medicine.
The study, led by Dr. Fatima Cardoso from the Champalimaud Foundation, involved women aged 18 to 70 undergoing endocrine therapy for HR-positive breast cancer or its prevention. Participants were randomly assigned to receive either a 120 mg dose of elinzanetant or a placebo daily.
The results showed a significant reduction in the frequency of moderate-to-severe vasomotor symptoms among those receiving elinzanetant. At week four, the elinzanetant group experienced a mean reduction of 6.5 episodes, compared to 3.0 episodes in the placebo group. By week 12, the reductions were 7.8 and 4.2 episodes, respectively.
Adverse events were reported in 69.8% of the elinzanetant group and 62.0% of the placebo group during the first 12 weeks. Serious adverse events occured in 2.5% and 0.6% of the respective groups.
“In a finding consistent with the results of previous trials involving postmenopausal women treatment with elinzanetant resulted in significant decreases in the frequency of vasomotor symptoms and in sleep disturbances and improvements in health-related quality of life among women with moderate-to-severe vasomotor symptoms taking endocrine therapy for breast cancer,” the authors write.
What’s next
Elinzanetant is under progress by Bayer. Further studies are expected to explore its long-term efficacy and safety,perhaps offering a valuable option for managing vasomotor symptoms in breast cancer patients on endocrine therapy.